Salih AKSU, Yahya BÜYÜKAŞIK, Hakan GÖKER, Haluk DEMİROĞLU, Elifcan ALADAĞ, Nilgün SAYINALP, Osman İlhami ÖZCEBE, İbrahim Celalettin HAZNEDAROĞLU, Mehmet TURGUT

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106 /kg. The aim of this study was to evaluate the relationship between the dose of CD34+ HPCs and survival in MM patients who underwent AHSCT at a tertiary care center. Materials and methods: Enrolled in this study were 271 MM patients who underwent AHSCT between 2003 and 2019. Clinical characteristics of the patients, disease status pre-AHSCT, reinfused CD34+ cell doses, and neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was

PDF

___

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE et al. Medical Research Council Adult Leukaemia Working P: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine 2003; 348 (19): 1875-1883. doi:10.1056/NEJMoa022340
2. Şahin U, Demirer T. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Journal of Clinical Apheresis 2018; 33 (3): 357-370. doi: 10.1002/jca.21591
3. Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT et al. Transplanted CD34(+) cell dose is associated with longterm platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biology of Blood Marrow Transplantation 2011; 17 (8): 1146-1153.doi: 10.1016/j. bbmt.2010.11.021
4. Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin BE et al. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Medical Oncology 2012; 29 (3): 2191-2199. doi:10.1007/ s12032-011-0029-3
5. Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells and Developments 2004; 13 (6): 598-606.doi:10.1089/ scd.2004.13.598
6. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation 2010; 16 (4): 490-499. doi:10.1016/j.bbmt.2009.11.012
7. Solmaz Medeni Ş, Türkyılmaz D, Acar C, Sevindik OG, Yüksel Fet al. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment? Turkish Journalof Hematology 2018; 35 (4): 271-276.doi: 10.4274/tjh.2018.0071
8. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23 (10): 1904-1912.doi: 10.1038/leu.2009.127
9. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. American journal of hematology 2018; 93 (8): 981-1114.doi:10.1002/ajh.25117
10. Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G et al. Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology 2011; 154 (1): 32-75.doi:10.1111/j.1365-2141.2011.08573.x
11. Gertz MA. Current status of stem cell mobilization. British Journal of Haematology 2010; 150(6):647-662.doi: 10.1111/j.1365-2141.2010.08313.x
12. Lanza F, Campioni DC, Hellmann A, Milone G, WahlinA et al. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biology of Bloodand Marrow Transplantation 2013; 19 (12): 1670-1676.doi:10.1016/j.bbmt.2013.08.005
13. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2000; 18 (6): 1360- 1377.doi:10.1200/JCO.2000.18.6.1360
14. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal 2019; 9 (4): 44.doi: 10.1038/s41408-019-0205-9
15. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86 (10): 3961-3969.
16. García de Veas Silva JL, Bermudo Guitarte C, Menendez Valladares P, Rojas Noboa JC, Kestler K et al. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients. PLoS One 2016; 11 (11): e0166841. doi: 10.1371/journal.pone.0166841